Abstract It is unknown whether dysregulated CSF1R himonocytes/macrophages drive the progression to diabetes and if their removal endogenous replacement with fresh macrophages resolves disease. Therefore, we hypothesize that depletion of activated CSF1R+ tissue using a monoclonal antibody against freshly differentiated will alleviate inflammation in tissues ameliorate diabetes-associated disease...